Nej Mo a 1109842
-
Upload
chriscahya-wibisana-candra -
Category
Documents
-
view
217 -
download
0
Transcript of Nej Mo a 1109842
-
8/10/2019 Nej Mo a 1109842
1/15
o r i gi n a l a r t i c l e
A Randomized Trial of Tenecteplase
versus Alteplase for Acute Ischemic StrokeMark Parsons, M.D., Neil Spratt, M.D.,Andrew Bivard, B.Sc.,
Bruce Campbell, M.D., Kong Cung, M.D., !erdinand Mite"", M.D.,Bill #$Brien, M.D., Cristoper Bladin, M.D., Patrick Mc%ldu"", P.D.,
Cris Allen, M.D., &rant Bateman, M.D., &eo""re' Donnan, M.D.,Stepen Davis, M.D., and Cristoper (evi, M.D.
ABSTRACT
T h e n e w e n gl a n d j o u r n a l o f m e d i c i n e
1
-
8/10/2019 Nej Mo a 1109842
2/15
T h e n e w e n gl a n d j o u r n a l o f m e d i c i n e
-
8/10/2019 Nej Mo a 1109842
3/15
BACKGROUND
Intravenous alteplase is the onl! approved treatment for acute ischemic stroke" Tenec#
teplase$ a geneticall! engineered mutant tissue plasminogen activator$ is an alternativethrom%ol!tic agent"
METHODS
In this phase B trial$ we randoml! assigned &' patients to receive alteplase ()"* mg per
kilogram of %od! weight+ or tenecteplase ()"1 mg per kilogram or )"' mg per kilo#gram+ less than , hours after the onset of ischemic stroke" To favor the selection of
patients most likel! to %enefit from throm%ol!tic therap!$ the eligi%ilit! criteria were aperfusion lesion at least )- greater than the infarct core on computed tomographic(CT+ perfusion imaging at %aseline and an associated vessel occlusion on CT angiog#
raph!" The coprimar! end points were the proportion of the perfusion lesion that wasreperfused at . hours on perfusion#weighted magnetic resonance imaging and the
e/tent of clinical improvement at . hours as assessed on the 0ational Institutes ofealth Stroke Scale (0ISS$ a .#point scale on which higher scores indicate more
severe neurologic deficits+"
RESULTS
The three treatment groups each comprised ' patients" The mean (2S3+ 0ISS scoreat %aseline for all patients was 1.".2",$ and the time to treatment was "*2)"4 hours"
Together$ the two tenecteplase groups had greater reperfusion (56)")).+ and clinicalimprovement (57)"))1+ at . hours than the alteplase group" There were no
significant %etween#group differences in intracranial %leeding or other serious ad#verse events" The higher dose of tenecteplase ()"' mg per kilogram+ was superior to
the lower dose and to alteplase for all efficac! outcomes$ including a%sence of seriousdisa%ilit! at *) da!s (in &- of patients$ vs" .)- with alteplase8 5 6 )")+"
CONCLUSIONS
Tenecteplase was associated with significantl! %etter reperfusion and clinical outcomes
than alteplase in patients with stroke who were selected on the %asis of CT perfusionimaging" (9unded %! the Australian 0ational ealth and :edical Research Council8Australia 0ew ;ealand Clinical Trials Registr! num%er$ ACTR01,)4))).,,
-
8/10/2019 Nej Mo a 1109842
4/15
h r o m % o l ! t i c t r e a t m e n t w i t h a l t e #
plase$ a recom%inant tissue plasminogenactivator$ for acute ischemic stroke is of
proven %enefit"1owever$ alteplase is far from
ideal$ with incomplete and often dela!ed reperfu#sion in man! patients"Tenecteplase$ a geneticall!
engineered mutant tissue plasminogen activator$
has some pharmacokinetic advantages over alte#plase"
-
8/10/2019 Nej Mo a 1109842
5/15
Table 1. Characteritic !" the Patie#t at Baeli#e.$
Characteritic Alte%lae &N ' ()*Te#ecte%lae
)>G* 9> )>G*
Diabetes mellitus 7 no. )H* 9 )G* F );:* > ):G*
Blood glucose 7 mmolliter >.GE9.9 .9E:.< .;E9.F
/'perlipidemia 7 no. )H* @ );>* 9; ):* 9 )>* G )9>*
Distal section o" "irst segment o" middle cerebral arter' ):
-
8/10/2019 Nej Mo a 1109842
6/15
STUDY O-ERSIGHT
The steering committee$ comprising five of the au#thors$ designed and oversaw the trial and vouches
for the completeness and accurac! of the data andthe anal!sis" The data anal!sis was undertaken %!
four of the authors" ?ne of the authors$ a %iostat#
istician$ was responsi%le for the un%linding of thetreatment assignments after the data%ase was
cleaned and locked$ and performed the prespeci#fied statistical anal!ses" Boehringer Ingelheim
sup#
-
8/10/2019 Nej Mo a 1109842
7/15
-
8/10/2019 Nej Mo a 1109842
8/15
outcomes$ at an alpha level of )")'$ in the pooled
tenecteplase groups"5rimar! h!potheses were tested %! means of
an unadjusted StudentFs t#test of means" Thisanal!sis was repeated after adjustment for poten#
tial confounding %aseline varia%les that differed%etween the alteplase and pooled tenecteplase
groups (57)"1)+ (Ta%le 1+" Secondar! outcomeswith a nonparametric distri%ution were tested with
the use of the =ilco/on rank#sum test$ and cat#egorical varia%les were compared with the use of
the chi#suare test of proportions or 9isherFs e/acttest" In the event of support for the primar! h!#
pothesis$ the protocol specified an anal!sis tocompare efficac! and safet! outcomes %etween thetwo tenecteplase groups and %etween each of the
tenecteplase groups and the alteplase group"
After the initial trial registration %ut %efore the
completion of the stud!$ the trial end points weremodified$ as informed %! several studies",$1SDTS
STUDY PATIENTS
9igure 1 shows the screening profile of the trial"
Between ))4 and )11$ a total of &,4 patientspresenting with strokelike s!mptoms underwent
screening within , hours after s!mptom onset8 ofthese patients$ &' (G 3ere treated wit alteplase outside trial;> 2nderwent endovascular terap'
G< /ad basilar1arter' occlusion:G 3ere treated wit alteplase outside trial9: 2nderwent endovascular terap'
FF /ad large core on C- per"usion imaging>G 3ere treated wit alteplase outside trial
9 3ere treated wit alteplase outside trial;> /ad occlusion but did not ave C-
per"usion mismatc
:G 3ere treated wit alteplase outside trial9 /ad poor18ualit' C-
9> 3ere treated wit alteplase outside trial:< /ad M+ contraindication
:< 3ere treated wit alteplase outside trial
9: 3ere potentiall' eligible "or tenecteplaseversus alteplase stud'
: Did not undergo randomiLationG< 3ere treated wit alteplase outside trial9: 2nderwent endovascular terap'
2nderwent randomiLation
: +eceived alteplase: +eceived tenecteplase,
-
8/10/2019 Nej Mo a 1109842
9/15
who were eligi%le for intravenous throm%ol!sis
%ut did not meet the CT criteria for this stud!received open#la%el alteplase (
-
8/10/2019 Nej Mo a 1109842
10/15
Table (. St/0 O/tc!+e i# the Alte%lae a#0 P!!le0 Te#ecte%lae Gr!/%.$
J
Plus0minus values are means ESD. (esion volumes are rounded to te nearest milliliter. -wo patients did not undergo M+at :G ours owing to clinical deterioration )one in te lower1dose tenecteplase group and one in te alteplase group* and werenot included in te anal'sis o" te primar' reper"usion outcome )or oter imaging1based e""icac' outcomes*. !ive patientsdied be"ore da' @< and were not included in te anal'sis o" in"arct growt at da' @
-
8/10/2019 Nej Mo a 1109842
11/15
Alte%lae
-
8/10/2019 Nej Mo a 1109842
12/15
Boehringer Ingelheim Australia and Ba!er Australia8 3r" 3avis$consultanc! fees from ?rsan Technologies and >ver 5harma8
and 3r" Devi$ consultanc! fees from Boehringer Ingelheim Aus#tralia" 0o other potential conflict of interest relevant to this ar#ticle was reported"
3isclosure forms provided %! the authors are availa%le withthe full te/t of this article at0>@:"org"
=e thank the stud! coo rdinators at each of the centers :ichelleRussell (central coordinator$ @ohn unter ospital+$ La%riel Silver
(Ro!al :el%ourne ospital+$ and ;ofia Ross (Bo/ ill ospital+"
http://nejm.org/http://nejm.org/http://nejm.org/ -
8/10/2019 Nej Mo a 1109842
13/15
REERENCES
T h e n e w e n gl a n d j o u r n a l o f m e d i c i n e
1
-
8/10/2019 Nej Mo a 1109842
14/15
1. Dees MR$ Bluhmki >$ vonMummer R$ et al" Time to
treatment with intravenousalteplase and outcome in
stroke an updated pooledanal!sis of >CASS$
ATDA0TIS$ 0I03S$ and>5IT>T trials" Dancet )1)8ffect of
incomplete (spontaneous andpostthrom%ol!tic+recanalization after middle
cere%ral arter! occlusion amagnetic resonance imaging
stud!" Stroke )).8C @r$ Thompson @D$Lrotta @C$ et al" 5hase IIBNIII
trial of tenecteplase in acuteischemic stroke results of aprematurel! terminated
randomized clinical trial"Stroke )1)8.1&)"
6. 5arsons :=$ :iteff 9$Bateman LA$ et al" Acuteischemic stroke imaging#guided tenecteplase treatment
in an e/#tended time window"0eurolog! ))*8& *1'#1"
7. acke =$ Maste :$ Bluhmki>$ et al" Throm%ol!sis withalteplase < to ."' hours after
acute ischemic stroke" 0 >ngl @:ed ))48ffects ofalteplase %e!ond < h afterstroke in the >choplanar
Imaging Throm%ol!tic>valuation Trial (>5IT>T+ a
place%ocontrolled randomisedtrial" Dancet 0eurol))48&**#
-
8/10/2019 Nej Mo a 1109842
15/15
# e 6 + (33 t h a # # i 5 e r a r 1 a r t i c l e
The 0>@: ))th Anniversar! cele%ration includes pu%lication of a seriesof invited review and 5erspective articles throughout )1"
>ach article e/plores a stor! of progress in medicine over the past )) !ears"
The collection of articles is availa%le at the 0>@: ))th Anniversar! we%site$httpNN0>@:))"0>@:"org "
T h e n e w e n gl a n d j o u r n a l o f m e d i c i n e
1 '
http://nejm200.nejm.org/http://nejm200.nejm.org/http://nejm200.nejm.org/